Collaboration agreements can comprise a variety of different organisations, each contributing complementary expertise and resources. Under some arrangements, one party may contribute the intellectual property (IP) while others bring the tools and market access required to commercialise the product. In other arrangements, the parties may collaborate on the product itself, each contributing different skills or technology to particular aspects of research, development and manufacture. In any case, collaborations allow parties to combine skills, share risk and accelerate innovation.
The following are important to get right in a successful and effective collaboration agreement:
1. Clear objective and governance
A successful collaboration agreement has a clearly defined project and scope. It should include a clear goal, timescales for completion and obligations for each party. The agreement should also set out how decisions are made, who has authority to approve key matters and what happens in the event of disagreement.
Failure to have in place a clear objective, timeline and defined governance procedures can lead to misaligned goals and potential disputes.
2. IP
IP is often one of the most heavily negotiated aspects of a life sciences collaboration agreement.
Parties should pay particular attention to 'background IP' (IP developed before the collaboration begins) and ensure that any rights granted in respect of background IP are sufficient to support the project while protecting valuable proprietary information.
The agreement should address improvements, modifications and inventions arising from the collaboration, including whether these fall within newly created IP and whether either party has rights to use them outside the project.
Detailed licensing arrangements are often required to ensure each party has the rights needed to develop, commercialise or otherwise exploit the project outputs. Where ownership of newly created IP is intended to sit with one party, the agreement should contain appropriate transfer provisions.
Although joint ownership is sometimes attractive in principle, it can create practical and legal difficulties around use, licensing and enforcement and should be considered carefully.
3. Data sharing and confidentiality
Effective collaboration depends on effective data sharing. Whether parties are exchanging research findings, technical information or clinical trial data, the agreement should establish a clear framework governing what data can be shared, who can access it and how it can be used.
The parties should also consider data ownership, security requirements, onward disclosure restrictions and whether rights to use the data continue after the collaboration ends. Addressing these issues early can help avoid disputes and ensure both parties can access the information needed to achieve the project's objectives.
Where personal data is involved, particularly in connection with clinical trials or patient studies, the agreement should clearly allocate data protection responsibilities and ensure compliance with the UK GDPR and the Data Protection Act 2018.
The parties should also consider whether data will be anonymised or pseudonymised, whether a separate data-sharing agreement is required and whether any restrictions should apply to the use of aggregated results or derived data after the collaboration ends.
4. Regulatory compliance
Life sciences collaborations often operate in a heavily regulated environment. The agreement should identify which regulatory requirements apply and allocate responsibility for satisfying them. Depending on the project, this may include clinical trial approvals, ethical approvals, consent forms and reporting responsibilities. Clearly allocating regulatory responsibilities at the outset can help avoid delay, duplication and uncertainty as the project develops.
5. Publication rights
Where universities, NHS bodies or research institutions are involved, the agreement should also address publication rights. In particular, it should set out whether either party may publish results or use them for internal research purposes, what review or approval process applies before publication and whether publication may be delayed to protect confidential information or patentable inventions.
6. Funding, fees and reimbursement
Collaboration agreements may require payment of some kind to be made by one party to another to assist it in carrying out the project.
There are several forms that payment may take:
Upfront fees: Payment made at the outset of the project.
Reimbursement: Payment of agreed costs incurred in carrying out the project.
Milestone payments: Payment made at agreed stages during the development of the project.
Royalties: Payment based on sales or commercialisation of the resulting product.
Each of these structures will suit different types of collaboration agreements. Nevertheless, it should be clear at the outset what form of payment will be adopted, if any. To avoid the risk of wasted expenditure, parties may also wish to include provisions setting out what the payment can be used for and what reporting or approval requirements apply.
7. Liability and risk allocation
The agreement should also allocate risk between the parties. This may include limitations of liability, indemnities, insurance requirements and responsibility for third-party claims. In life sciences collaborations, particular attention should be given to liability arising from regulatory breaches, misuse of data, infringement of third-party IP, failed trials or defective products.
8. Termination provisions
Termination provisions are an important part of any collaboration agreement, as are the corresponding rights and obligations on termination for the other parties. The agreement should define which grounds can be used to terminate the agreement, such as material breach, insolvency of one of the parties or where the agreement is no longer capable of being fulfilled or is no longer commercially viable. The latter is particularly important to ensure parties are not locked into a collaboration that no longer delivers sufficient value or commercial benefit.
Parties should also consider the consequences of termination. Factors to consider include what happens to any data, confidential information and ownership of any project materials. The agreement should also specify which provisions survive termination, such as confidentiality, IP rights, data-use restrictions, payment obligations, liability provisions and dispute resolution mechanisms. Effective termination provisions reduce the risk of disputes arising.
Conclusion
Collaboration agreements are an effective way for life sciences organisations to combine expertise, share risk and accelerate innovation. To maximise the prospects of success, parties should focus on the fundamentals from the outset: clear objectives, robust governance, well-considered IP provisions, practical data-sharing arrangements, appropriate regulatory responsibilities, agreed payment structures, effective risk allocation and clear termination rights.
As Scotland's life sciences sector continues to grow, well-structured collaboration agreements will remain an important tool in turning innovation into commercial and societal impact.
